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Extramedullary relapse (EMR) of acute leukemia (AL) after allogeneic hematopoietic stem cell transplantation
(allo-HSCT) is a contributor to post-transplantation mortality and remains poorly understood, especially the
different characteristics of EMR in patients with acute myelogenous leukemia (AML) and those with acute
lymphoblastic leukemia (ALL). To investigate the incidence, risk factors, and clinical outcomes of EMR for AML
and ALL, we performed a retrospective analysis of 362 patients with AL who underwent allo-HSCT at the First
afﬁliated Hospital of Soochow University between January 2001 and March 2012. Compared with patients
with AML, those with ALL had a higher incidence of EMR (12.9% versus 4.6%; P ¼ .009). The most common site
of EMR was the central nervous system, especially in the ALL group. Multivariate analyses identiﬁed the
leading risk factors for EMR in the patients with AML as advanced disease status at HSCT, hyperleukocytosis at
diagnosis, history of extramedullary leukemia before HSCT, and a total body irradiationebased conditioning
regimen, and the top risk factors for EMR in the patients with ALL as hyperleukocytosis at diagnosis, adverse
cytogenetics, and transfusion of peripheral blood stem cells. The prognosis for EMR of AL is poor, and
treatment options are very limited; however, the estimated 3-year overall survival (OS) was signiﬁcantly
lower in patients with AML compared with those with ALL (0 versus 18.5%; P ¼ .000). The characteristics of
posteallo-HSCT EMR differed between the patients with AML and those with ALL, possibly suggesting
different pathogenetic mechanisms for EMR of AML and EMR of ALL after allo-HSCT; further investigation is
needed.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION University between January 2001 and March 2012. We studied
Although allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT) is a potentially curative treatment for
patients with acute leukemia (AL), relapse remains the most
frequent cause of treatment failure and mortality. In partic-
ular, a signiﬁcant rate of extramedullary relapse (EMR) after
allo-HSCT has been reported [1-6], with a poor prognosis.
Although risk factors for EMR have been described in
patients with acute myelogenous leukemia (AML), few
studies have compared the different characteristics of EMR in
patients with AML and patients with acute lymphoblastic
leukemia (ALL) in the post-HSCT setting.
In an effort to better understand post-HSCT EMR, we
performed a retrospective analysis on 362patientswith ALwho
underwent allo-HSCT in the First afﬁliated Hospital of Soochowedgments on page 1046.
equests: Xiaowen Tang and Depei Wu,
fﬁliated Hospital of Soochow University,
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edmail.com (D. Wu), xwtang1020@
2014 American Society for Blood and Marrow
14.03.030the incidence, risk factors, treatments, outcomes, and mecha-
nisms of post-HSCT EMR in patients with ALL and AML.
PATIENTS AND METHODS
Patients
A total of 362 patients with AL who underwent allo-HSCT in our
institution between January 2001 and March 2012 were enrolled in this
retrospective study, including 208 patients with AML, 147 with ALL, and 7
with acute mixed lineage leukemia (AMLL). These patients included 204
males and 158 females, with a median age of 32 years (range, 3 to 63 years).
The graft donor sources for allo-HSCT were unrelated in 27.1% of cases,
sibling in 58.3%, and haploidentical in 14.6%; 79.6% of the transplants were
HLA-matched. Stem cell sources included bone marrow (BM) in 45.6%,
peripheral blood (PB) stem cells (PBSCs) in 36.5%, and BM plus PBSCs in
17.9%. In this study, 260 patients (71.8%) received a modiﬁed busulfan
(Bu)/cyclophosphamide (Cy) conditioning regimen, 89 (24.6%) received a
total body irradiation (TBI)/Cy regimen, and 13 (3.6%) received a non-
myeloablative conditioning regimen. Patient characteristics are summarized
in Table 1. Patients were treated according to clinical protocols approved by
the Institutional Review Board and/or institutional care practice guidelines
of Soochow University.
Conditioning Regimen
Of the 362 patients, 260 patients received a modiﬁed Bu/Cy regimen
(Me-CCNU 250 mg/m2/day on day -10, Ara-C 4 g/m2/day on days 9 to 8,
Transplantation.
Table 1
Clinical Characteristics of 362 Patients with AL Post-HSCT
Characteristic AML
(n ¼ 208)
ALL
(n ¼ 147)
AMLL
(n ¼ 7)
Age, yr, median (range) 35 (3-63) 25 (4-57) 26 (20-54)
Sex, n
Male 116 83 5
Female 92 64 2
Hyperleukocytosis at diagnosis, n 66 52 1
EM leukemia before HSCT, n 14 13 0
High cytogenetic risk, n 20 65 3
Disease status at HSCT, n
CR1 163 110 5
CR2 23 36 0
NR 22 1 2
Conditioning regimen, n
Bu/Cy 185 72 3
TBI/Cy 11 74 4
NST 12 1 0
Stem cell source, n
BM 100 62 3
PB 72 58 2
BM þ PB 36 27 2
Donor type, n
Sibling 142 66 3
URD 43 53 2
Haploidentical 23 28 2
aGVHD grade, n
I-II 67 51 5
III-IV 13 9 0
cGVHD, n 61 38 3
NR indicates no remission; NST, nonmyeloablative conditioning regimen;
URD, unrelated donor.
L. Ge et al. / Biol Blood Marrow Transplant 20 (2014) 1040e1047 1041Bu 0.8 to 1 mg/kg/6 hours on days7 to5, and Cy 1.8 g/m2/day on days4
to 3) as a preparative regimen, and 89 patients received a TBI/Cy regimen
consisting of fractionated TBI 12 Gy on days 8 to 6, Ara-C 2 g/m2/day on
day 5, and Cy 1.8 g/m2/day on days 4 to 3. Thirteen patients received
nonmyeloablative Bu/ﬂudarabine (Flu) conditioning regimen (Bu 0.8 mg/kg/
6 hour on days 6 to 5, Flu 30 mg/m2/day on days 7 to 2, and Ara-C
0.5 g/m2/day on days 8 to 4).
Graft-Versus-Host Disease Prophylaxis
Acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD)
were classiﬁed according to the criteria proposed by Przepiorka et al. [7] and
Sullivan [8]. GVHD prophylaxis included cyclosporine A with short-term
methotrexate for related identical transplantation and cyclosporine A,
methotrexate, mycophenolate mofetil, and human antithymocyte globulin
for unrelated and haploidentical transplantation. The haploidentical grafts
were noneT cell depleted.
Central Nervous System Relapse Prophylaxis after Transplantation
Prophylactic intrathecal chemotherapy (with methotrexate or cytosine
arabinoside and dexamethasone) each month for 6 months wasFigure 1. (A) Cumulative incidence of EMR after allo-HSCT for AL. EMR with or withou
with concurrent BMR (dashed line), 4.7% (n ¼ 15). (B) Cumulative incidence of EMRadministered to all patients with ALL and high-risk AML in the ﬁrst year
after allo-HSCT.
Deﬁnitions and Statistical Analysis
EMR included isolated EMR and EMR with concurrent bone marrow
relapse (BMR); isolated EMR was deﬁned as EMR without concurrent BMR.
EMR was diagnosed in most cases by magnetic resonance imaging,
computed tomography, or positron emission tomography. Histological
conﬁrmation was performed whenever possible. Central nervous system
(CNS) relapse was diagnosed when leukemic cells were identiﬁed in the
cerebrospinal ﬂuid. Isolated CNS relapsewas deﬁned as CNS relapse without
any other sites of leukemia relapse. Clinical remission (CR) was deﬁned as
<5% blasts in the BM with normal complete blood count values. High-risk
cytogenetics was deﬁned as complex karyotype, 5q-, monosomy 7/7q-,
and/or FLT-3epositive for AML and MLL gene rearrangement and/or
Philadelphia chromosome in ALL. Hyperleukocytosis was deﬁned as a
peripheral WBC count >50  109/L at diagnosis of AML, B lymphoblastic
leukemia as >30  109/L, and T lymphoblastic leukemia as >100  109/L.
The cumulative incidence estimation for leukemia relapse was deter-
mined by treating death as a competing risk and was compared using the
method of Gray [9]. Overall survival (OS) was calculated from the date of
relapse post-transplantation to death or last follow-up for censored cases,
and was estimated using the Kaplan-Meier method and compared with a
log-rank test. Continuous variables were compared with the Mann-Whitney
test, and categorical variables were compared with the chi-square test. A
comprehensive multivariate analysis of risk factors for relapse was esti-
mated using the Cox proportional hazards regression model. All statistical
analyses were performedwith SPSS version 16.0 (SPSS Inc, Chicago, IL) and R
version 2.15.1 (R Project for Statistical Computing, Vienna, Austria).
RESULTS
Patient Characteristics
We retrospectively analyzed a consecutive series of 362
patients with AL who underwent allo-HSCT in our single
institution. Of these 362 patients, 163 of 208 with AML,110 of
147 with ALL, and 5 of 7 with AMLL were in ﬁrst CR status
(CR1) at the time of allo-HSCT. After transplantation, 40.1%
patients experienced aGVHD, including 34.0% with mild
(grade I-II) and 6.1% with severe (grade III-IV) aGVHD, and
28.2% patients developed cGVHD. After a follow-up ranging
from 1 month to 139 months (median, 17 months), 90 pa-
tients (24.9%) developed either EMR or BMR; 64 of these
relapsed patients had isolated BMR only, 11 had isolated
EMR, and 15 had EMR with concurrent BMR.
Incidence and Characteristics of EMR in AL
The estimated 10-year cumulative incidence of overall
relapse posteallo-HSCT was 27%. That of EMR was 7.9%, with
3.1% of patients experiencing isolated EMR. Compared with
patients with AML, those with ALL had a higher estimated
10-year cumulative incidence of EMR (12.9% versus 4.6%;
P ¼ .009) (Figure 1).t BMR (dotted line), 7.9% (n ¼ 26); isolated EMR (solid line), 3.1% (n ¼ 11); EMR
after HSCT for AML versus ALL (4.6% versus 12.9%; P ¼ .009).
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allo-HSCT, including 11 with isolated EMR and 15 with EMR
and concurrent BMR. Of these latter 15 patients, 6 who
initially had EMR later developed BMR, 4 with BMR later
developed EMR, and the remaining 5 developed EMR and
BMR almost simultaneously. In our center, the median time
to BMR post-HSCTwas 5months (range,1 to 60months), and
the median time to EMR was 4 months (range, 1 to
38 months; P ¼ .879). Involved extramedullary (EM) sites
included the CNS, testis, skin, soft tissue, bone, lymph nodes,
nasopharynx, and peritoneum. Multifocal involvement at
EMR was observed in 5 of 26 patients (19.2%). CNS relapse
(n ¼ 18) was the most common type of EMR, with a cumu-
lative incidence of 5.4%, whereas the cumulative incidence of
isolated CNS relapse was 2.5%.
Among the 26 patients who developed EMR, 5 had a
history of EM leukemia before undergoing allo-HSCT, all of
whom relapsed at the same site as in the previous leukemia.
Ten patients had mild aGVHD (grade I-II), 3 had severe
aGVHD (grade III-IV), and 3 developed cGVHD before the
onset of EMR. Characteristics of the 11 patients who had
isolated EMR and the 15 patients who had EMR with con-
current BMR are presented in Tables 2 and 3.
Risk Factors for Overall Relapse and EMR in AL
We analyzed the variables of interest by Cox proportional
hazard modeling to identify risk factors for AL relapse,
including age, sex, disease type, donor type, stem cell source,
hyperleukocytosis at diagnosis, cytogenetic risk, disease
status at HSCT, HLA mismatch, conditioning regimen, EM
leukemia before HSCT, aGVHD, and cGVHD. The results of our
univariate and multivariate analyses are summarized in
Tables 4 and 5.
In terms of overall relapse, our multivariate analyses
showed that patients with high-risk cytogenetics, advanced
disease status, TBI-based conditioning regimen, without
cGVHD, and male sex were more likely to relapse (Table 4).
The multivariate analyses also revealed a higher rate of EMR
in patients with high-risk cytogenetics, advanced disease
status, and male sex (relative risk [RR] ¼ 3.860, P ¼ .002;
RR ¼ 6.663, P ¼ .003; and RR ¼ 2.844, P ¼ .038, respectively).
A history of EM leukemia before undergoing HSCT and
hyperleukocytosis at diagnosis also correlated with an
increased risk of EMR (RR ¼ 3.011; P ¼ .038 and RR ¼ 3.382;
P ¼ .004, respectively). Meanwhile, patients who received
PBSC grafts were more likely to develop EMR (RR ¼ 5.495;
P ¼ .002) (Table 5).Table 2
Characteristics of Patients with AL Who Developed Isolated EMR after HSCT
Patient Sex Age,
yr
Disease Disease
Status
at HSCT
EM Leukemia
before HSCT
Donor Type Stem
Sour
1 F 31 ALL CR1 No URD PB
2 M 22 ALL CR1 No URD PB
3 M 36 ALL CR1 No URD PB
4 F 22 ALL CR2 No Haploidentical PB
5 M 48 ALL CR2 No Sibling PB
6 M 10 ALL CR3 CNS Haploidentical BM
7 M 44 ALL CR4 No Sibling PB
8 F 35 ALL CR1 No Sibling BM
9 M 18 ALL CR2 Lymph
nodes
URD PB
10 M 44 AML CR1 No Sibling BM
11 M 29 AML CR2 CNS Haploidentical PBTo identify differences in pathogenesis between BMR and
EMR, we performed further analyses with separate consid-
eration of isolated BMR. Patients with advanced disease
status had a higher frequency of BMR, and also were more
likely to develop EMR. Multivariate analyses also revealed
that the patients without cGVHD were more likely to
experience BMR (RR ¼ 5.907; P ¼ .000); however, there was
no signiﬁcant difference in the incidence of EMR between
patients with cGVHD and those without cGVHD. In addition,
the incidence of BMR was higher in patients who received
a TBI-based conditioning regimen or nonmyeloablative
conditioning regimen compared with patients who received
a Bu-containing regimen (RR ¼ 2.100; P ¼ .012 versus
RR ¼ 3.159; P ¼ .031) (Table 5).Differences in Risk Factors for EMR in AML and ALL
To identify differences in the pathogenesis of EMR be-
tween patients with AML and those with ALL, we performed
further multivariate analyses with these 2 groups of patients
separately. We found that in the patients with AML,
advanced disease status, a history of EM leukemia before
HSCT, use of a TBI-based conditioning regimen, and hyper-
leukocytosis at diagnosis were associated with a higher fre-
quency of EMR (RR ¼ 16.264, P ¼ .001; RR ¼ 10.416, P ¼ .011;
RR¼ 10.455, P¼ .035; and RR¼ 4.699, P¼ .041, respectively),
whereas in the patients with ALL, the top risk factors for EMR
were receipt of PBSC grafts, hyperleukocytosis at diagnosis,
and high-risk cytogenetics (RR ¼ 6.015, P ¼ .007; RR ¼ 2.996,
P ¼ .032; and RR ¼ 2.889, P ¼ .042, respectively) (Table 6).Postrelapse Treatment and Clinical Outcomes in AL
Four patients refused any treatment and died of relapse.
The remaining 22 patients who experienced EMR with or
without BMR received various treatment modalities. Nine
patients developed isolated CNS relapse and were treated
with intrathecal chemotherapy and/or cranial irradiation.
One patient who experienced EMR in both the CNS and
peritoneum received local chemotherapy, and another pa-
tient who developed EMR in lymph nodes was treated with
chemotherapy and donor lymphocyte infusion (DLI); how-
ever, both patients died of progressive disease. Eight patients
received chemotherapy, followed by local irradiation and
DLI; 7 of these patients achieved CR, and 2 were still sur-
viving as of the date of this report. The other 5 patients died
of GVHD, leukemia recurrence, or CNS relapse. Two patients
received chemotherapy and local irradiation, and both diedCell
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L. Ge et al. / Biol Blood Marrow Transplant 20 (2014) 1040e1047 1043from leukemia recurrence. The remaining patient was
treated with supportive care and died of progressive disease.
In general, the estimated 3-year OS postrelapse was bet-
ter in patients with isolated EMR than in patients with BMR
only and those with EMR with concurrent BMR, but the
differencewas not statistically signiﬁcant (18.2% versus 12.0%
versus 8.0%; P ¼ .206) (Figure 2). Although the median OS
postrelapse was 9 months versus 4 months versus 4 months,
these differences were not signiﬁcance either (P ¼ .099).
However, the estimated 3-year OS in these patients with
EMR was signiﬁcantly lower in those with AML compared
with those with ALL (0 versus 18.5%; P ¼ .000).
DISCUSSION
EMR after allo-HSCT is relatively rare and not well stud-
ied. Although most previous studies reported on patients
with AML, there are too little data comparing characteristics
of EMR between patients with AML and patients with ALL. To
our knowledge, this is the ﬁrst report to examine the dif-
ferences in EMR occurring after allo-HSCT in patients with
AML and those with ALL. We found that signiﬁcant differ-
ences between the 2 groups of patients.
The incidence of EMR after allo-HSCT varies among
transplantation centers, ranging from 6% to 20% in single-
institution reports [5,6,10-12]; however, in a retrospective
European Group for Blood and Marrow Transplantation
(EBMT) survey, the incidence of post-HSCT EMR was only
0.65% in patients with AML [1]. The lower incidence of EMR
found in that multicenter study may be related to under-
reporting in retrospective registry data, as well as to the
greater number of patients reported in recent series owing to
longer follow-up, longer survival, and generally improved
outcomes of HSCT [4]. In general, the incidence of EMR is
higher in patients with ALL compared with those with AML
[4-6]. In our center, the estimated 10-year cumulative inci-
dence of overall post-HSCT relapse in patients with AL was
27%; that of EMRwas 7.9%, with 3.1% of patients experiencing
isolated EMR. The incidence of EMR was 12.9% in patients
with ALL and 4.6% in those with AML (P ¼ .009).
Historical risk factors for EMR after HSCT include Phila-
delphia chromosomeepositive AL, AML subtype M4/M5, age
<18 years at diagnosis, EM leukemia before HSCT, adverse
cytogenetics, relapse/refractory disease at transplantation,
Bu/Cy preconditioning, and CD56 and T cell marker expres-
sion [4,6,13,14]. In the present study, identiﬁed risk factors
included EM leukemia before HSCT, adverse cytogenetics,
and relapse/refractory disease at transplantation, consistent
with previous studies [4,6,13]; however, AML subtype M4/
M5 and Bu/Cy preconditioning were not risk factors in our
study cohort. In addition, we identiﬁed male sex, hyper-
leukocytosis at diagnosis, TBI-based conditioning regimen,
and transfusion of PBSCs as risk factors for EMR. These
ﬁndings have not been reported previously in the post-HSCT
setting; probable reasons for this include the following:
1. The incidence of EMR was high in our male patients
owing to the relatively high rate of EMR with a testis
leukemia subtype in our cohort (5 of 26).
2. Hyperleukocytosis has been identiﬁed as a risk
factor for CNS involvement, but not in the post-
transplantation setting [15]; we also found it corre-
lated with an increased risk of EMR after allo-HSCT.
Patients with hyperleukocytosis had a high tumor
burden, which facilitates the inﬁltration of tumor cells
to EM sites.
Table 4
Univariate and Multivariate Analyses of Risk Factors for Overall Relapse in Patients with AL (n ¼ 90)
Factor Univariate RR (95% CI) P Value Multivariate RR (95% CI) P Value
Sex, male/female 1.826 (1.168-2.853) .008 1.696 (1.082-2.657) .021
Age, 18 yr/>18 yr 1.565 (0.960-2.551) .072
Disease
AML 1.000
ALL 1.756 (1.154-2.672) .009
AMLL 1.598 (0.386-6.613) .518
Donor type
Sibling 1.000
URD 1.522 (0.942-2.459) .086
Haploidentical 2.361 (1.375-4.052) .002
HLA mismatch/match 1.732 (1.084-2.767) .022
Stem cell source
BM 1.000
PB 1.302 (0.817-2.077) .267
BM þ PB 1.376 (0.791-2.393) .258
Hyperleukocytosis at diagnosis, yes/no 1.223 (0.799-1.873) .354
Cytogenetic risk, high/intermediate-low 2.190 (1.428-3.357) .000 1.704 (1.054-2.755) .030
Disease status at HSCT
CR1 1.000 1.000
CR2 2.621 (1.605-4.282) .000 1.838 (1.087-3.110) .023
NR 5.140 (2.844-9.289) .000 7.123 (3.855-13.163) .000
EM leukemia before HSCT, yes/no 1.617 (0.812-3.220) .172
Conditioning regimen
Bu/Cy 1.000 1.000
TBI/Cy 2.147 (1.384-3.329) .001 1.846 (1.112-3.064) .018
NST 1.686 (0.610-4.658) .314 2.262 (0.806-6.349) .121
aGVHD, no/yes 0.857 (0.564-1.303) .471
cGVHD, no/yes 4.547 (2.282-9.059) .000 5.127 (2.551-10.304) .000
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regarding pretransplantation conditioning regimens.
One retrospective study found a higher incidence of
isolated EMR associated with Bu/Cy regimensle 5
variate and Multivariate Analyses of Risk Factors for EMR (n ¼ 26) and BMR (n ¼ 6
actor EMR
Univariate RR
(95% CI)
P Value Multivariate RR
(95% CI)
P V
ex, male/female 3.486 (1.314-9.250) .012 2.844 (1.060-7.631) .038
ge, 18/>18 yr 2.224 (0.967-5.117) .060
isease
AML 1.000
ALL 2.911 (1.296-6.539) .010
AMLL 0.000 (0.000-) .977
onor type
Sibling 1.000
URD 2.464 (1.025-5.926) .044
Haploidentical 3.236 (1.170-8.950) .024
LA mismatch/match 1.735 (0.727-4.140) .214
tem cell source
BM 1.000
PB 4.425 (1.605-12.199) .004 5.495 (1.880-16.062) .002
BM þ PB 3.271 (0.998-10.719) .050 2.583 (0.752-8.870) .132
yperleukocytosis at
diagnosis, yes/no
2.394 (1.107-5.176) .027 3.382 (1.484-7.707) .004
ytogenetic risk, high/
intermediate-low
2.999 (1.385-6.495) .005 3.860 (1.647-9.045) .002
isease status at HSCT
CR1 1.000
CR2 2.770 (1.126-6.813) .026 1.154 (0.431-3.087) .775
NR 4.451 (1.467-13.505) .008 6.663 (1.923-23.085) .003
M leukemia before
HSCT, yes/no
3.427 (1.291-9.093) .013 3.011 (1.064-8.521) .038
onditioning regimen
Bu 1.000
TBI 2.645 (1.210-5.780) .015
NST 0.000 (0.000) .979
GVHD, no/yes 0.635 (0.294-1.371) .248
GVHD, no/yes 3.694 (1.108-12.320) .033compared with TBI-containing regimens [14]. This
result may be related to the low plasma levels of Bu
achieved in some patients [16]; however, other more
controversial results failed to show such a difference4) in Patients with AL
BMR
alue Univariate RR
(95% CI)
P Value Multivariate RR
(95% CI)
P Value
1.543 (0.926-2.572) .096
1.434 (0.780-2.636) .247
1.000
1.509 (0.916-2.484) .106
2.005 (0.480-8.376) .340
1.000
1.249 (0.697-2.236) .455
2.098 (1.105-3.983) .024
1.737 (0.996-3.029) .052
1.000
0.855 (0.484-1.510) .589
1.120 (0.588-2.135) .730
0.961 (0.566-1.630) .881
2.013 (1.201-3.375) .008
1.000 1.000
2.598 (1.447-4.664) .001 2.052 (1.098-3.835) .024
5.488 (2.728-11.043) .000 7.387 (3.593-15.189) .000
1.029 (0.374-2.833) .955
1.000 1.000
1.959 (1.151-3.334) .013 2.100 (1.179-3.739) .012
2.247 (0.802-6.292) .123 3.159 (1.114-8.956) .031
0.958 (0.580-1.584) .868
5.085 (2.193-11.791) .000 5.907 (2.531-13.784) .000
Table 6
Characteristics of Patients with AML and Patients with ALL
Characteristics EMR in AML (n ¼ 9) EMR in ALL (n ¼ 17) P Value
Cumulative incidence, % 4.60 12.90 .009
EMR site, n*
CNS 5 13 .382
Testis 2 3 1.000
Skin/soft tissue 3 1 .104
Bone 1 1 1.000
Lymph nodes 0 1 1.000
Nasopharynx 0 1 1.000
Peritoneum 0 1 1.000
EM leukemia before HSCT, n 2 3 1.000
Risk factorsy
Hyperleukocytosis at diagnosis (RR ¼ 4.699; P ¼ .041) Hyperleukocytosis at diagnosis (RR ¼ 2.996;
P ¼ .032)
Advanced disease status (RR ¼ 16.264; P ¼ .001) High-risk cytogenetics (RR ¼ 2.889; P ¼ .042)
EM leukemia before HSCT (RR ¼ 10.416; P ¼ .011) PB stem cell source (RR ¼ 6.015; P ¼ .007)
TBI-based conditioning regimen (RR ¼ 10.455; P ¼ .035)
Type of therapy, n
Local 2 8 .399
Systemic 4 7 1.000
None 3 2 .302
Estimated 3-yr OS, % 0 18.50 .000
* Five of 26 patients (19%) presented with extramedullary disease in multiple sites.
y The variables were analyzed by Cox proportional hazard modeling to identify the risk factors for relapse, including age, sex, donor type, stem cell source,
hyperleukocytosis at diagnosis, cytogenetic risk, disease status at HSCT, HLA mismatch, conditioning regimen, EM leukemia before HSCT, aGVHD and cGVHD,
ALL with or without the Philadelphia chromosome, and AML subtype M4/M5.
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of CNS relapse in patients who received TBI-containing
preconditioning, possibly because a signiﬁcantly
higher proportion of patients with CNS leukemia
received such a regimen compared with those without
CNS leukemia (81.5% versus 57.9%; P< .001). The role of
conditioning regimen in preventing EMR has not been
evaluated precisely. In our study, use of a TBI-
containing regimen was associated with a higher
incidence of EMR compared with use of a Bu/Cy
regimen in the patients with AML, but not in those
with ALL. This differencemay be related to the fact that
all 11 patients with AMLwho received a TBI-containing
regimenwere high-risk patients; 5 had a history of EM
leukemia before HSCT, 3 patients were not in remissionre 2. Estimated 3-year OS for patients with AL relapse post-HSCT. Isolated
R (solid line), 18.2%; isolated BMR (dashed line), 12.0%; EMR with concur-
t BMR (dotted line), 8.0%; P ¼ .206.at transplantation, 2 patients were in CR2 or greater
(CR2) at transplantation, and 1 patient had adverse
cytogenetics.
4. Transplantation of PBSCs was identiﬁed as a risk factor
for EMR. A possible explanation for this may be the
higher rate of CR2/refractory disease status at the
time of transplantation in the patients who received
PBSC grafts compared with those who received BM
grafts (28.8% versus 15.1%; P ¼ .004). Another possible
explanation is that transfusion of PBSCs may be related
to the presence of a graft-versus-leukemia (GVL) effect
that did not protect EM sites after allo-HSCT. The
increased incidence of GVHD in patients with EMR
implies that GVL surveillance preferentially maintains
remission in the BM while allowing leukemic cells in
peripheral tissues to evade immune surveillance [13].
Furthermore, we identiﬁed transfusion of PBSCs as a
independent risk factor for EMR in patients with ALL,
but not in those with AML, suggesting that the GVL
effect may be less effective at EM sites in ALL. This may
be related to the induction of T cell anergy by ALL
cells [19], inadequate expression of important cos-
timulatory molecules or adhesion molecules [20,21],
or ALL resistance to killing by natural killer cells [22].
Previous research also has shown that the GVL effect
may be less effective at EM sites in patients with AML
[10,23,24]. The patient heterogeneity and small sample
size in a single transplantation center preclude draw-
ing conclusions regarding the association of EMR and
these risk factors; multicenter studies with larger
numbers of patients are needed.
In the present study, the development of cGVHD was
protective against relapse in the BM, but this protective effect
did not extend to EM sites. Multivariate analyses showed that
the patients without cGVHD were more likely to experience
BMR. This ﬁnding suggests that the pathogenesis of EMR
differs from that of BMR and identiﬁes the EM sites as
potential sanctuary sites for leukemia cells, possibly because
L. Ge et al. / Biol Blood Marrow Transplant 20 (2014) 1040e10471046of decreased expression of HLA minor histocompatibility
antigens and adhesion molecules [25].
To date, there are no standardized therapeutic strategies
for EMR. Generally, some combination of systemic and local
therapy should be considered, given that local therapy alone
often results in subsequent systemic relapse. Local therapy
includes surgical excision, intrathecal injection, and/or ra-
diation, and systemic therapy involves immunotherapy with
chemotherapy, DLI, and second allo-HSCT. The optimal
therapeutic strategy remains controversial, however. Recent
studies have reported good treatment response with some
immune-targeting drugs, including gemtuzumab ozogami-
cin [26], a recombinant humanized monoclonal antibody
that targets the CD33 antigen, which is expressed in >90% of
leukemic cells. Sorafenib, a multikinase inhibitor, has sig-
niﬁcant activity against FLT3-ITDþ blasts in vitro and
demonstrated encouraging clinical results as a single agent
[27] and in combinationwith chemotherapy [28] for patients
with AML and the FLT3-ITDmutation. Either agentmay be an
effective therapeutic choice for EMR after allo-HSCT [29,30].
Recently, hypomethylating agents, such as 5-azacitidine and
decitabine, were successfully used in the salvage treatment
of patients with AMLwho relapsed or experienced EMR after
allo-HSCT [31-33]. It was hypothesized that hypomethylating
agents are directly cytotoxic and also might increase the GVL
effect by inducing leukemic cell differentiation and expres-
sion of HLA-DR to enhance the effects of DLI given
concomitantly [33,34].
Owing to a lack of effective treatments, the prognosis for
EMR after allo-HSCT is poor. Generally, patients with isolated
EMR have a better prognosis than thosewith BMR [10]. In the
UK Medical Research Council’s UKALL12/ECOG 2993 study
[35], analysis of outcomes in 609 adults with recurring ALL
revealed a better 5-year OS in patients with EMR compared
with patients with BMR and thosewith BMR and CNS relapse
(14% versus 6% versus 0; P ¼ .004). The Children’s Oncology
Group CCG-1961 study [36] reported obvious differences in
the 3-year OS of childhood ALL in patients with BMR (with or
without EMR), those with isolated CNS EMR, and those with
other isolated EMR (29.7% versus 52.2% versus 68.2%;
P < .0001, log-rank test). In the multicenter trial Acute
Lymphoblastic Leukemia Relapse Berlin-Frankfurt-Münster
90 [37], multivariate Cox regression analysis identiﬁed the
site of relapse as an independent predictor for event-free
survival (RR for subsequent event at an isolated EM site
versus combined and isolated BM sites of relapse of 1,1.7, and
2.3, respectively; P < .001). In the present study, in the post-
HSCT setting, we also found a trend toward better prognosis
in patients with isolated EMR compared with patients with
BMR or systemic relapse (18.2% versus 12.0% versus 8.0%;
P ¼ .206). In addition, our patients with ALL had a signiﬁ-
cantly higher estimated 3-year OS compared with those with
AML, possibly related to the higher proportion of isolated
EMR in the patients with ALL. Thus, treatment should focus
on preventing systemic relapse [13].
In conclusion, our results reported here demonstrate that
EMR after allo-HSCT poses a signiﬁcant challenge for trans-
plantation physicians. Our patients with ALL had a higher
cumulative incidence of EMR compared with those with
AML. CNS relapse is the most common subtype of EMR. Pa-
tients with high-risk cytogenetics, advanced disease status,
history of EM leukemia before allo-HSCT, hyperleukocytosis
at diagnosis, receipt of PBSCs blood stem cell, and male are at
increased risk for EMR. These patients should be closely
evaluated for early evidence of EMR. 18F-ﬂuorodeoxyglucosepositron emission tomography/computed tomography may
be a useful tool for this purpose [38]. Prophylactic intrathecal
chemotherapy [39] and low-dose azacitidine or decitabine
administered after allo-HSCT [33,40] may reduce the rate of
recurrence. The prognosis for EMR after allo-HSCT is poor,
and efﬁcacious treatment strategies are lacking. In addition
to an early diagnosis with new modalities, clinical studies
using new agents that may offer systemic activity while
preserving the GVL effect are warranted in an effort to
improve clinical outcomes. Considering the limitations of
this study and previous related studies, including single
institution experience, small sample size of patients with
EMR, and patient heterogeneity, future studies with larger
numbers of patients are warranted to further deﬁne the
incidence, risk factors, and appropriate therapeutic strategies
for EMR after allo-HSCT.ACKNOWLEDGMENTS
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